|
1
|
Greenlee RT, Hill-Harmon MB, Murray T and
Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen KY, Chang CH, Yu CJ, Kuo SH and Yang
PC: Distribution according to histologic type and outcome by gender
and age group in Taiwanese patients with lung carcinoma. Cancer.
103:2566–2574. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yoshimi I, Ohshima A, Ajiki W, Tsukuma H
and Sobue T: A comparison of trends in the incidence rate of lung
cancer by histological type in the Osaka cancer registry, Japan and
in the Surveillance, Epidemiology and End Results Program, USA. Jpn
J Clin Oncol. 33:98–104. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Toh CK and Lim WT: Lung cancer in
never-smokers. J Clin Pathol. 60:337–340. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu NS, Spitz MR, Kemp BL, Cooksley C,
Fossella FV, et al: Adenocarcinoma of the lung in young patients:
The M. D. Anderson experience. Cancer. 88:1837–1841. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan BA and Hughes BG: Targeted therapy
for non-small cell lung cancer: Current standards and the promise
of the future. Transl Lung Cancer Res. 4:36–54. 2015.PubMed/NCBI
|
|
7
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roh MS: Molecular pathology of lung
cancer: Current status and future directions. Tuberc Respir Dis
(Seoul). 77:49–54. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wagner T, Wirth J, Meyer J, Zabel B, Held
M, et al: Autosomal sex reversal and campomelic dysplasia are
caused by mutations in and around the SRY-related gene SOX9. Cell.
79:1111–1120. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Foster JW, Dominguez-Steglich MA, Guioli
S, Kwok C, Weller PA, et al: Campomelic dysplasia and autosomal sex
reversal caused by mutations in an SRY-related gene. Nature.
372:525–530. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang SS, Fang WT, Hou YH, Huang SF, Yen
BL, et al: Upregulation of SOX9 in lung adenocarcinoma and its
involvement in the regulation of cell growth and tumorigenicity.
Clin Cancer Res. 16:4363–4373. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Müller P, Crofts JD, Newman BS,
Bridgewater LC, Lin CY, et al: SOX9 mediates the retinoic
acid-induced HES-1 gene expression in human breast cancer cells.
Breast Cancer Res Treat. 120:317–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lü B, Fang Y, Xu J, Wang L, Xu F, et al:
Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol.
130:897–904. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang H, Leav I, Ibaragi S, Wegner M, Hu
GF, et al: SOX9 is expressed in human fetal prostate epithelium and
enhances prostate cancer invasion. Cancer Res. 68:1625–1630. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou CH, Ye LP, Ye SX, et al: Clinical
significance of SOX9 in human non-small cell lung cancer
progression and overall patient survival. J Exp Clin Cancer Res.
31:182012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sirma H, Broemel M, Stumm L, Tsourlakis T,
Steurer S, et al: Loss of CDKN1B/p27Kip1 expression is associated
with ERG fusion-negative prostate cancer, but is unrelated to
patient prognosis. Oncol Lett. 6:1245–1252. 2013.PubMed/NCBI
|
|
17
|
Südbeck P, Schmitz ML, Baeuerle PA and
Scherer G: Sex reversal by loss of the C-terminal transactivation
domain of human SOX9. Nat Genet. 13:230–232. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lynn FC, Smith SB, Wilson ME, Yang KY,
Nekrep N and German MS: Sox9 coordinates a transcriptional network
in pancreatic progenitor cells. Proc Natl Acad Sci USA.
104:10500–10505. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Piper K, Ball SG, Keeling JW, Mansoor S,
Wilson DI and Hanley NA: Novel SOX9 expression during human
pancreas development correlates to abnormalities in Campomelic
dysplasia. Mech Dev. 116:223–226. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thomsen MK, Butler CM, Shen MM and Swain
A: Sox9 is required for prostate development. Dev Biol.
316:302–311. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang H, McKnight NC, Zhang T, Lu ML, Balk
SP and Yuan X: SOX9 is expressed in normal prostate basal cells and
regulates androgen receptor expression in prostate cancer cells.
Cancer Res. 67:528–536. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Blache P, van de Wetering M, Duluc I,
Domon C, Berta P, et al: SOX9 is an intestine crypt transcription
factor, is regulated by the Wnt pathway, and represses the CDX2 and
MUC2 genes. J Cell Biol. 166:37–47. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Passeron T, Valencia JC, Bertolotto C,
Hoashi T, Le Pape E, et al: SOX9 is a key player in ultraviolet
B-induced melanocyte differentiation and pigmentation. Proc Natl
Acad Sci USA. 104:13984–13989. 2007. View Article : Google Scholar : PubMed/NCBI
|
